These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17031397)

  • 1. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.
    Duran I; Kortmansky J; Singh D; Hirte H; Kocha W; Goss G; Le L; Oza A; Nicklee T; Ho J; Birle D; Pond GR; Arboine D; Dancey J; Aviel-Ronen S; Tsao MS; Hedley D; Siu LL
    Br J Cancer; 2006 Nov; 95(9):1148-54. PubMed ID: 17031397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
    BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
    Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
    J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
    Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
    Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
    Italiano A; Kind M; Stoeckle E; Jones N; Coindre JM; Bui B
    Anticancer Drugs; 2011 Jun; 22(5):463-7. PubMed ID: 21301319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
    Kruczek K; Ratterman M; Tolzien K; Sulo S; Lestingi TM; Nabhan C
    Br J Cancer; 2013 Oct; 109(7):1711-6. PubMed ID: 24008662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
    Advani AS; Mahfouz RZ; Maciejewski J; Rybicki L; Sekeres M; Tripp B; Kalaycio M; Bates J; Saunthararajah Y
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):172-177.e1. PubMed ID: 24332215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
    J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
    Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
    BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
    Behbakht K; Sill MW; Darcy KM; Rubin SC; Mannel RS; Waggoner S; Schilder RJ; Cai KQ; Godwin AK; Alpaugh RK
    Gynecol Oncol; 2011 Oct; 123(1):19-26. PubMed ID: 21752435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
    Reungwetwattana T; Molina JR; Mandrekar SJ; Allen-Ziegler K; Rowland KM; Reuter NF; Luyun RF; Dy GK; Marks RS; Schild SE; Jett JR; Adjei AA
    J Thorac Oncol; 2012 May; 7(5):919-22. PubMed ID: 22722792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.